PF-06700841 for Scarring Alopecia

"As evidenced by clinicaltrials.gov, this trial is actively canvassing for participants. This research project was initially posted on May 21st 2021 and the most recent update happened on August 16th 2022."

"Currently, there are three active clinical trials for PF-06700841 running in 39 countries and 143 cities. The first of these studies began back in 2018; sponsored by Pfizer it had 246 participants and concluded its phase 2 drug approval stage. To date, 18331 additional trials have already been completed since then."

"According to the study sponsor, Pfizer, over a Week 48 interval they will measure the primary outcome of Changes from baseline in CCL5 gene expression level in response to PF-06700841. Alongside this primary outcome, secondary outcomes such as The Lichen Planopilaris Activity Index (LPPAI), which rates symptoms and signs on a 0-10 scale with higher scores indicating more severe conditions; Changes from baseline in CXCL10 gene expression levels measured by quantitative real-time PCR assay at different points throughout the trial; and Changes from baseline in CXCL9 gene expression levels also measured via quantitative real-"

"Currently, 3 different trials are studying PF-06700841 with none of them in the final stage. The bulk of these studies occur within Koscian and Milan; however, there are 422 medical centres conducting research for this drug."

"A score of 2 was attributed to PF-06700841 due to preclinical evidence indicating some safety, but there is yet insufficient proof that the compound can be effective in treating a given condition."

"Affirmative. Clinicaltrials.gov corroborates that this research endeavour, which was first made accessible on May 21st 2021, is currently recruiting volunteers. The study will have a total of 48 participants at one medical facility."